1. Home
  2. ACRV vs RECT Comparison

ACRV vs RECT Comparison

Compare ACRV & RECT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ACRV
  • RECT
  • Stock Information
  • Founded
  • ACRV 2018
  • RECT 1997
  • Country
  • ACRV United States
  • RECT Singapore
  • Employees
  • ACRV N/A
  • RECT N/A
  • Industry
  • ACRV Medicinal Chemicals and Botanical Products
  • RECT
  • Sector
  • ACRV Health Care
  • RECT
  • Exchange
  • ACRV Nasdaq
  • RECT Nasdaq
  • Market Cap
  • ACRV 47.8M
  • RECT 53.6M
  • IPO Year
  • ACRV 2022
  • RECT 2024
  • Fundamental
  • Price
  • ACRV $1.52
  • RECT $4.00
  • Analyst Decision
  • ACRV Buy
  • RECT
  • Analyst Count
  • ACRV 7
  • RECT 0
  • Target Price
  • ACRV $17.40
  • RECT N/A
  • AVG Volume (30 Days)
  • ACRV 3.4M
  • RECT 27.2K
  • Earning Date
  • ACRV 11-12-2025
  • RECT 07-31-2025
  • Dividend Yield
  • ACRV N/A
  • RECT N/A
  • EPS Growth
  • ACRV N/A
  • RECT N/A
  • EPS
  • ACRV N/A
  • RECT 0.12
  • Revenue
  • ACRV N/A
  • RECT $32,594,177.00
  • Revenue This Year
  • ACRV N/A
  • RECT N/A
  • Revenue Next Year
  • ACRV $805.34
  • RECT N/A
  • P/E Ratio
  • ACRV N/A
  • RECT $33.76
  • Revenue Growth
  • ACRV N/A
  • RECT 5.91
  • 52 Week Low
  • ACRV $1.05
  • RECT $2.78
  • 52 Week High
  • ACRV $10.00
  • RECT $7.68
  • Technical
  • Relative Strength Index (RSI)
  • ACRV 56.53
  • RECT 40.88
  • Support Level
  • ACRV $1.30
  • RECT $3.60
  • Resistance Level
  • ACRV $2.67
  • RECT $4.98
  • Average True Range (ATR)
  • ACRV 0.19
  • RECT 0.32
  • MACD
  • ACRV 0.02
  • RECT -0.08
  • Stochastic Oscillator
  • ACRV 16.06
  • RECT 45.25

About ACRV Acrivon Therapeutics Inc.

Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.

About RECT Rectitude Holdings Ltd Ordinary Shares

Rectitude Holdings Ltd is principally involved in the provision of safety equipment, encompassing essential items such as personal protective clothing, hand gloves, safety footwear, and personal fall arrest systems (a system used to arrest an employee in a fall from a walking-working surface, usually consisting of a body harness, anchorage, and connector), portable fire extinguishers and traffic products such as rubber speed humps, wheel stops and wheel chocks. Additionally the company has added auxiliary products such as industrial hardware tools and electrical hardware required for construction sites.

Share on Social Networks: